Positive top-line Phase III for ZS Pharma's hyperkalemia drug
This article was originally published in Scrip
Executive Summary
ZS Pharma has reported positive top-line results from the initial 'acute' part of a pivotal Phase III trial of its lead drug candidate ZS-09, a new treatment for hyperkalemia, at the ASN Kidney Week 2013 annual meeting in Atlanta, GA, over the weekend.